Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 2:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 479 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Manifestations Clear all
Recruiting Phase 4 Interventional

Optimizing Perioperative Analgesia to Lower Pain Following Cleft Palate Surgery

NCT06962306
View directory record Official record
Conditions
Cleft Palate, Pain, Postoperative Care, Perioperative Care, Children
Interventions
Methadone hydrochloride, Fentanyl/Hydromorphone
Drug
Lead sponsor
Duke University
Other
Eligibility
6 Months to 4 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

NCT00857623
View directory record Official record
Conditions
Pain, Diabetic Neuropathy
Interventions
AZD2066, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Bella Vista, Arkansas • National City, California • Walnut Creek, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 13, 2026, 2:03 AM EDT
Enrolling by invitation Phase 3 Interventional

Extended Oral Tranexamic Acid After Total Knee Arthroplasty

NCT06618820
View directory record Official record
Conditions
Osteo Arthritis Knee, Pain, Postoperative
Interventions
Tranexamic acid, Placebo
Drug
Lead sponsor
Campbell Clinic
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers

NCT06258213
View directory record Official record
Conditions
Gout, Acute Gout Flare, Gout Flares
Interventions
ABP-745, Placebo
Drug
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 13, 2026, 2:03 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

NCT06782490
View directory record Official record
Conditions
Multiple Sclerosis Spasticity
Interventions
BMS-986368, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 13, 2026, 2:03 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

NCT01433978
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Eltrombopag, Avatrombopag, Standard of care
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Watertown, South Dakota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 13, 2026, 2:03 AM EDT
Terminated Not applicable Interventional

Use of Sucrose to Relieve Pain During Eye Exams in Infants

NCT00161694
View directory record Official record
Conditions
Apnea of Prematurity, Retinopathy of Prematurity, Pain
Interventions
sucrose solution
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
5 Weeks and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2008 · Synced Oct 13, 2026, 2:03 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Nd:YAG Laser Photobiostimulation on Healing of Gingiva

NCT07095556
View directory record Official record
Conditions
Wound Healing and Prevention, Oral Inflammation, Photobiomodulation, Post-operative Pain Management, Tooth Extraction Site Healing
Interventions
Low-level laser therapy
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Olanzapine for Acute Headaches

NCT03066622
View directory record Official record
Conditions
Headache
Interventions
Standard of Care as per attending physician, 5mg rapidly dissolving olanzapine
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 13, 2026, 2:03 AM EDT
Terminated Phase 2 Interventional

Percocet vs. Bupivicaine for Toothaches in the ED

NCT02862691
View directory record Official record
Conditions
Toothache
Interventions
Acetaminophen/Oxycodone (Oral analgesic), Bupivicaine (Injectable local anesthetic)
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Tolerance and Experimental Hyperalgesia Study of Oral NGX426 in Healthy Male Voluneteers

NCT00832546
View directory record Official record
Conditions
Healthy, Hyperalgesia
Interventions
Placebo, Oral NGX426 (Powder in solution)
Drug
Lead sponsor
TorreyPines Therapeutics
Industry
Eligibility
21 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2009 · Synced Oct 13, 2026, 2:03 AM EDT
Recruiting Phase 4 Interventional

Duloxetine for LBP

NCT05851976
View directory record Official record
Conditions
Back Pain, Low
Interventions
Naproxen, Duloxetine
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Chronic Pain Risk Associated With Menstrual Period Pain

NCT02214550
View directory record Official record
Conditions
Cystitis, Interstitial, Dysmenorrhea, Migraine Disorders, Pelvic Pain, Endometriosis, Visceral Pain, Chronic Pain
Interventions
cyclic microgestin 1/20, continuous microgestin 1/20
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Oral Rivaroxaban in Children With Venous Thrombosis

NCT01684423
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Active comparator, Rivaroxaban (BAY59-7939) suspension
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

NCT01118962
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 13, 2026, 2:03 AM EDT
Terminated Phase 3 Interventional

S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat

NCT00006994
View directory record Official record
Conditions
Cancer-related Problem/Condition, Head and Neck Cancer, Pain
Interventions
glutamine, radiation therapy, l-glutamine placebo
Dietary Supplement · Radiation · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
106
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Oral PhenazopyrIdine on Perioperative Voiding After Mid-urethral sliNg (EPIPhANy Study)

NCT02806713
View directory record Official record
Conditions
Dysfunctional Voiding, Postoperative Pain
Interventions
Phenazopyridine, no Phenazopyridine
Drug · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 13, 2026, 2:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease

NCT06158620
View directory record Official record
Conditions
Post Operative Pain, Urolithiasis, Ureter Calculi, Stent Complication
Interventions
intra-nasal ketorolac, oral diclofenac
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 2 Interventional

A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee

NCT02524197
View directory record Official record
Conditions
Osteoarthritis
Interventions
CR845 0.25 mg, CR845 0.50 mg, CR845 1 mg, CR845 5 mg
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
25 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Omaha, Nebraska • Las Vegas, Nevada • Greensboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 13, 2026, 2:03 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Medrol Dosepak for Outpatient Total Knee Arthroplasty

NCT05097976
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Methylprednisolone, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Oak Brook, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Reduction in Pain Intensity Following IV or Oral Pain-relieving Products

NCT02678416
View directory record Official record
Conditions
Pain
Interventions
IV Acetaminophen (Treatment A), Oral Acetaminophen (Treatment B), Placebo (Treatment C), Morphine (Treatment D)
Drug · Other
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Not applicable Interventional

Determination of the Safety and Effectiveness of an Oral Rinse in the Reduction of Medication Associated Metallic Taste

NCT02992314
View directory record Official record
Conditions
Medication Associated Metallic Taste , Dysgeusia
Interventions
Metaqil™ Oral Rinse, Placebo
Device
Lead sponsor
You First Services
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 13, 2026, 2:03 AM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT05387707
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 13, 2026, 2:03 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of MEB-1170 in Healthy Subjects

NCT05748119
View directory record Official record
Conditions
Pain
Interventions
MEB-1170, Placebo
Drug
Lead sponsor
Mebias Discovery, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 13, 2026, 2:03 AM EDT